Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 63

1.

Can stroma reaction predict cancer lethality?

Freeman MR, Li Q, Chung LW.

Clin Cancer Res. 2013 Sep 15;19(18):4905-7. doi: 10.1158/1078-0432.CCR-13-1694. Epub 2013 Sep 5.

2.

Fibrous stroma is associated with poorer prognosis in lung squamous cell carcinoma patients.

Takahashi Y, Ishii G, Taira T, Fujii S, Yanagi S, Hishida T, Yoshida J, Nishimura M, Nomori H, Nagai K, Ochiai A.

J Thorac Oncol. 2011 Sep;6(9):1460-7. doi: 10.1097/JTO.0b013e318229189d.

3.

Elevated CXCL1 expression in breast cancer stroma predicts poor prognosis and is inversely associated with expression of TGF-β signaling proteins.

Zou A, Lambert D, Yeh H, Yasukawa K, Behbod F, Fan F, Cheng N.

BMC Cancer. 2014 Oct 24;14:781. doi: 10.1186/1471-2407-14-781.

4.

Stromal expression of hypoxia regulated proteins is an adverse prognostic factor in colorectal carcinomas.

Cleven AH, van Engeland M, Wouters BG, de Bruïne AP.

Cell Oncol. 2007;29(3):229-40.

5.

Neoplastic and stromal cells contribute to an extracellular matrix gene expression profile defining a breast cancer subtype likely to progress.

Triulzi T, Casalini P, Sandri M, Ratti M, Carcangiu ML, Colombo MP, Balsari A, Ménard S, Orlandi R, Tagliabue E.

PLoS One. 2013;8(2):e56761. doi: 10.1371/journal.pone.0056761. Epub 2013 Feb 18.

6.

Identification of prognostic molecular features in the reactive stroma of human breast and prostate cancer.

Planche A, Bacac M, Provero P, Fusco C, Delorenzi M, Stehle JC, Stamenkovic I.

PLoS One. 2011;6(5):e18640. doi: 10.1371/journal.pone.0018640. Epub 2011 May 18.

7.

Stromal MCP-1 in mammary tumors induces tumor-associated macrophage infiltration and contributes to tumor progression.

Fujimoto H, Sangai T, Ishii G, Ikehara A, Nagashima T, Miyazaki M, Ochiai A.

Int J Cancer. 2009 Sep 15;125(6):1276-84. doi: 10.1002/ijc.24378.

8.

Stromal ING1 expression induces a secretory phenotype and correlates with breast cancer patient survival.

Thakur S, Nabbi A, Klimowicz A, Riabowol K.

Mol Cancer. 2015 Aug 27;14:164. doi: 10.1186/s12943-015-0434-x.

9.

Transcriptional mimicry by tumor-associated stroma.

Kim H, Verhaak RG.

Nat Genet. 2015 Apr;47(4):307-9. doi: 10.1038/ng.3255.

PMID:
25814306
10.

Understanding the role of stromal fibroblasts in cancer progression.

Tripathi M, Billet S, Bhowmick NA.

Cell Adh Migr. 2012 May-Jun;6(3):231-5. doi: 10.4161/cam.20419. Epub 2012 May 1. Review.

11.

Future directions in the field of endometrial cancer research: the need to investigate the tumor microenvironment.

Felix AS, Weissfeld J, Edwards R, Linkov F.

Eur J Gynaecol Oncol. 2010;31(2):139-44. Review.

12.

Stromal expression of MiR-21 predicts biochemical failure in prostate cancer patients with Gleason score 6.

Melbø-Jørgensen C, Ness N, Andersen S, Valkov A, Dønnem T, Al-Saad S, Kiselev Y, Berg T, Nordby Y, Bremnes RM, Busund LT, Richardsen E.

PLoS One. 2014 Nov 17;9(11):e113039. doi: 10.1371/journal.pone.0113039. eCollection 2014.

13.

Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ.

Sharma M, Beck AH, Webster JA, Espinosa I, Montgomery K, Varma S, van de Rijn M, Jensen KC, West RB.

Breast Cancer Res Treat. 2010 Sep;123(2):397-404. doi: 10.1007/s10549-009-0654-0. Epub 2009 Dec 1.

14.

Lumican and versican are associated with good outcome in stage II and III colon cancer.

de Wit M, Belt EJ, Delis-van Diemen PM, Carvalho B, Coupé VM, Stockmann HB, Bril H, Beliën JA, Fijneman RJ, Meijer GA.

Ann Surg Oncol. 2013 Dec;20 Suppl 3:S348-59. doi: 10.1245/s10434-012-2441-0. Epub 2012 Jun 19.

15.

Prognostic impact of platelet-derived growth factors in non-small cell lung cancer tumor and stromal cells.

Donnem T, Al-Saad S, Al-Shibli K, Andersen S, Busund LT, Bremnes RM.

J Thorac Oncol. 2008 Sep;3(9):963-70. doi: 10.1097/JTO.0b013e3181834f52.

16.

Comprehensive genomic meta-analysis identifies intra-tumoural stroma as a predictor of survival in patients with gastric cancer.

Wu Y, Grabsch H, Ivanova T, Tan IB, Murray J, Ooi CH, Wright AI, West NP, Hutchins GG, Wu J, Lee M, Lee J, Koo JH, Yeoh KG, van Grieken N, Ylstra B, Rha SY, Ajani JA, Cheong JH, Noh SH, Lim KH, Boussioutas A, Lee JS, Tan P.

Gut. 2013 Aug;62(8):1100-11. doi: 10.1136/gutjnl-2011-301373. Epub 2012 Jun 26.

PMID:
22735568
17.

Hurthle cell carcinoma with myxoid stroma - a rare entity and a diagnosis pitfall.

Li C, Mazhari M, Perera M, Rana DN.

Cytopathology. 2010 Apr;21(2):120-2. doi: 10.1111/j.1365-2303.2009.00704.x. Epub 2010 Jan 6. No abstract available.

PMID:
20059506
18.

Dangerous liaisons: pancreatic stellate cells and pancreatic cancer cells.

Apte MV, Wilson JS.

J Gastroenterol Hepatol. 2012 Mar;27 Suppl 2:69-74. doi: 10.1111/j.1440-1746.2011.07000.x. Review.

PMID:
22320920
19.

Next generation sequencing-based expression profiling identifies signatures from benign stromal proliferations that define stromal components of breast cancer.

Guo X, Zhu SX, Brunner AL, van de Rijn M, West RB.

Breast Cancer Res. 2013 Dec 17;15(6):R117. doi: 10.1186/bcr3586.

20.

Stroma and pancreatic ductal adenocarcinoma: an interaction loop.

Luo G, Long J, Zhang B, Liu C, Xu J, Ni Q, Yu X.

Biochim Biophys Acta. 2012 Aug;1826(1):170-8. doi: 10.1016/j.bbcan.2012.04.002. Epub 2012 Apr 13. Review.

PMID:
22521638

Supplemental Content

Support Center